Eunice Kennedy Shriver National Institute of Child Health and Human Development; Notice of Meeting, 13495-13496 [2018-06258]
Download as PDF
Federal Register / Vol. 83, No. 61 / Thursday, March 29, 2018 / Notices
licensing in accordance with 35 U.S.C.
209 and 37 CFR part 404 to achieve
expeditious commercialization of
results of federally-funded research and
development. Technology description
follows.
sradovich on DSK3GMQ082PROD with NOTICES
Lentiviral Protein Delivery System for
RNA-Guided Genome Editing
Description of Technology: This
invention provides an HIV–1-based
lentiviral vector system for gene
correction strategies involving a
homologous recombination with a
variation of the CRISPR/Cas9 system.
Such systems are being explored as
potential therapies for certain hereditary
diseases. This system comprises (a) a
lentivirus vector particle comprising a
lentiviral genome which encodes at
least one guide RNA sequence that is
complementary to a first DNA sequence
in a host cell genome, (b) a Cas9 protein,
and optionally (c) a donor nucleic acid
molecule comprising a second DNA
sequence. In addition, the invention
provides a host cell comprising the
foregoing system, as well as a method of
altering a DNA sequence in a host cell
comprising contacting a host cell with
the foregoing system. Alternatively, the
invention also provides a fusion protein
comprising a Cas9 protein and a
cyclophilin A (CypA) protein, wherein
the fusion protein binds to the lentivirus
vector particle, as well as a lentiviral
vector particle comprising such a fusion
protein. Other such lentivirus-based
vectors encode a guide RNA, which
contains a specific sequence that
recognizes a target gene, and a Cas9
endonuclease, which cuts at the specific
site. However, such systems present
some problems due to constitutive
expression of Cas9 endonuclease in
lentiviral vector-transduced cells and
the large size of the Cas9 gene. The
variation of this invention delivers the
Cas9 endonuclease directly, instead of
the gene encoding the protein.
Potential Commercial Applications:
Clinical trials for hereditary diseases
such as sickle-cell disease and betathalassemia are good market
opportunities. Gene correction using the
disclosed lentiviral vector system are
being tested with respect to the betaglobin gene and the BCL11A gene to
treat sickle-cell disease and will be used
for induced pluripotent stem cell (iPS)
generation.
Development Stage: Early-stage. In
vitro data in cell-line models available.
Inventors: Naoya Uchida, Juan J. Haro
Mora and John F. Tisdale (NHLBI).
Intellectual Property: US Application
No. 62/236,223, filed October 2, 2015
and PCT/US2016/054759, filed
VerDate Sep<11>2014
19:09 Mar 28, 2018
Jkt 244001
September 30, 2016, (NIH Reference No.
E–165–2015/0,1).
Publications: Lentiviral protein
delivery system for RNA-guided genome
editing, PCT Publication No. WO/2017/
059241, published April 6, 2017.
Licensing Contact: Cristina
Thalhammer-Reyero, Ph.D., M.B.A.;
301–435–4507; thalhamc@mail.nih.gov.
Collaborative Research Opportunity:
The National Heart, Lung and Blood
Institute is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize this technology. For
collaboration opportunities, please
contact Denise Crooks at crooksd@
mail.nih.gov.
Dated: March 22, 2018.
Cristina Thalhammer-Reyero,
Senior Licensing and Patenting Manager,
Office of Technology Transfer and
Development, National Heart, Lung, and
Blood Institute.
[FR Doc. 2018–06364 Filed 3–28–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health and Human
Development; Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Board of Scientific
Counselors, NICHD.
The meeting will be open to the
public as indicated below, with the
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
Eunice Kennedy Shriver National
Institute Of Child Health And Human
Development, including consideration
of personnel qualifications and
performance, and the competence of
individual investigators, the disclosure
of which would constitute a clearly
unwarranted invasion of personal
privacy.
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
13495
Name of Committee: Board of Scientific
Counselors, NICHD.
Date: June 1, 2018.
Open: 8:00 a.m. to 11:45 a.m.
Agenda: A report by the Scientific Director,
NICHD, on the status of the NICHD Division
of Intramural Research; talks by various
intramural scientists, and current
organizational structure.
Place: National Institutes of Health,
Building 31A, Conference Room 2A48, 31
Center Drive, Bethesda, MD 20892.
Closed: 11:45 a.m. to 4:00 p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health,
Building 31A, Conference Room 2A48, 31
Center Drive, Bethesda, MD 20892.
Contact Person: Constantine A. Stratakis,
MD, D(med)Sci, Scientific Director, Eunice
Kennedy Shriver National Institute of Child
Health and Human Development, NIH,
Building 31A, Room 2A46, 31 Center Drive,
Bethesda, MD 20892, 301–594–5984,
stratakc@mail.nih.gov.
Information is also available on the
Institute’s/Center’s home page: https://
www.nichd.nih.gov/about/meetings/Pages/
index.aspx, where an agenda and any
additional information for the meeting will
be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos.93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: March 23, 2018.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–06259 Filed 3–28–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health and Human
Development; Notice of Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Advisory Board on Medical
Rehabilitation Research. The meeting
will be open to the public, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: National Advisory
Board on Medical Rehabilitation Research.
E:\FR\FM\29MRN1.SGM
29MRN1
13496
Federal Register / Vol. 83, No. 61 / Thursday, March 29, 2018 / Notices
Date: May 7–8, 2018.
Time: May 7, 2018, 9:00 a.m. to 5:00 p.m.
Agenda: NICHD Director’s report;
Inclusion at NIH; Clinical Trials Policy
Updates; Update on NIH Rehabilitation
Research Plan Analysis; Communication and
Dissemination Strategies; Pathways to
Prevention.
Place: NICHD Offices, 6710B Rockledge
Drive, Rooms 1425/1427, Bethesda, MD
20892.
Time: May 8, 2018, 8:30 a.m. to 12:00 p.m.
Agenda: Pragmatic Trials at NIH;
Rehabilitation 2030: WHO Effort; Scientific
Presentation on Multimodal Approaches.
Place: NICHD Offices, 6710B Rockledge
Drive, Rooms 1425/1427, Bethesda, MD
20892.
Contact Person: Ralph M. Nitkin, Ph.D.,
Deputy Director, National Center for Medical
Rehabilitation Research (NCMRR), Eunice
Kennedy Shriver National Institute of Child
Health and Human Development, NIH,
DHHS, 6710B Rockledge Drive, Room 2116,
MSC 7002, Bethesda, MD 20892, (301) 402–
4206, RN21e@nih.gov.
Information is also available on the
Institute’s/Center’s home page: https://
www.nichd.nih.gov/about/advisory/nabmrr/
Pages/index.aspx where the current roster
and minutes from past meetings are posted.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: March 23, 2018.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–06258 Filed 3–28–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
[Docket No. USCG–2018–0042]
Chemical Transportation Advisory
Committee; Vacancies
U.S. Coast Guard, Department
of Homeland Security.
ACTION: Request for applications.
AGENCY:
The U.S. Coast Guard seeks
applications for membership on the
Chemical Transportation Advisory
Committee. The Chemical
Transportation Advisory Committee
provides advice and makes
recommendations on matters relating to
the safe and secure marine
transportation of hazardous materials
insofar as they relate to matters within
the United States Coast Guard’s
jurisdiction.
sradovich on DSK3GMQ082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
19:09 Mar 28, 2018
Jkt 244001
Completed applications should
reach the U.S. Coast Guard on or before
May 29, 2018.
ADDRESSES: Applicants should send a
cover letter expressing interest in an
appointment to the Chemical
Transportation Advisory Committee that
also identifies which membership
category the applicant is applying
under, along with a resume detailing the
applicant’s experience via one of the
following methods:
• By Email: jake.r.lobb2@uscg.mil;
Subject Line: Chemical Transportation
Advisory Committee;
• By Fax: (202) 372–8380 ATTN:
Lieutenant Jake Lobb; or
• By Mail: Lieutenant Jake Lobb,
Alternate Designated Federal Official of
the Chemical Transportation Advisory
Committee, Commandant, Hazardous
Materials Division (CG–ENG–5), U.S.
Coast Guard, 2703 Martin Luther King
Jr. Ave. SE, Stop 7509, Washington, DC
20593–7509.
FOR FURTHER INFORMATION CONTACT:
Lieutenant Jake Lobb of the Chemical
Transportation Advisory Committee;
(202) 372–1428; jake.r.lobb2@uscg.mil.
SUPPLEMENTARY INFORMATION: The
Chemical Transportation Advisory
Committee is a federal advisory
committee which operates under the
provisions of the Federal Advisory
Committee Act, 5 U.S.C. Appendix.
The Chemical Transportation
Advisory Committee provides advice
and recommendations to the
Department of Homeland Security on
matters relating to the safe and secure
marine transportation of hazardous
materials insofar as they relate to
matters within the United States Coast
Guard’s jurisdiction.
The Chemical Transportation
Advisory Committee meets at least
twice per year. It may also meet for
extraordinary purposes. Its
subcommittees may meet to consider
specific problems as required.
The U.S. Coast Guard will consider
applications for 8 positions that become
vacant on September 16, 2018. The
membership categories are: Chemical
manufacturing, marine handling or
transportation of chemicals, vessel
design and construction, marine safety
or security, and marine environmental
protection. All members of the Chemical
Transportation Advisory Committee are
Representatives. Each Chemical
Transportation Advisory Committee
member serves for a term of three years,
and may serve no more than two
consecutive three-year terms. A member
appointed to fill an unexpired term may
serve the remainder of that term. All
members serve at their own expense and
DATES:
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
receive no salary, reimbursement of
travel expenses, or other compensation
from the Federal Government.
The Department of Homeland
Security does not discriminate in
selection of Committee members on the
basis of race, color, religion, sex,
national origin, political affiliation,
sexual orientation, gender identity,
marital status, disabilities and genetic
information, age, membership in an
employee organization, or any other
non-merit factor. The Department of
Homeland Security strives to achieve a
widely diverse candidate pool for all of
its recruitment actions.
If you are interested in applying to
become a member of the Committee,
send your cover letter and resume to
Lieutenant Jake Lobb, Alternate
Designated Federal Official of the
Chemical Transportation Advisory
Committee, via one of the transmittal
methods in the ADDRESSES section by
the deadline in the DATES section of this
notice. All email submittals will receive
email receipt confirmation.
Dated: March 23, 2018.
Jeffrey G. Lantz,
Director, Commercial Regulations and
Standards.
[FR Doc. 2018–06385 Filed 3–28–18; 8:45 am]
BILLING CODE 9110–04–P
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[Docket ID: FEMA–2018–0012; OMB No.
1660–NEW]
Agency Information Collection
Activities: Proposed Collection;
Comment Request; National
Catastrophic Resource Catalog
U.S. Fire Administration,
Federal Emergency Management
Agency, DHS.
ACTION: Notice and request for
comments.
AGENCY:
The Federal Emergency
Management Agency (FEMA), as part of
its continuing effort to reduce
paperwork and respondent burden,
invites the general public to take this
opportunity to comment on a new
information collection. In accordance
with the Paperwork Reduction Act of
1995, this notice seeks comments
concerning the identification and
cataloging of fire and emergency
services personnel and equipment that
might be available to support a
catastrophic national disaster response.
SUMMARY:
E:\FR\FM\29MRN1.SGM
29MRN1
Agencies
[Federal Register Volume 83, Number 61 (Thursday, March 29, 2018)]
[Notices]
[Pages 13495-13496]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-06258]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National Institute of Child Health and
Human Development; Notice of Meeting
Pursuant to section 10(a) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
National Advisory Board on Medical Rehabilitation Research. The meeting
will be open to the public, with attendance limited to space available.
Individuals who plan to attend and need special assistance, such as
sign language interpretation or other reasonable accommodations, should
notify the Contact Person listed below in advance of the meeting.
Name of Committee: National Advisory Board on Medical
Rehabilitation Research.
[[Page 13496]]
Date: May 7-8, 2018.
Time: May 7, 2018, 9:00 a.m. to 5:00 p.m.
Agenda: NICHD Director's report; Inclusion at NIH; Clinical
Trials Policy Updates; Update on NIH Rehabilitation Research Plan
Analysis; Communication and Dissemination Strategies; Pathways to
Prevention.
Place: NICHD Offices, 6710B Rockledge Drive, Rooms 1425/1427,
Bethesda, MD 20892.
Time: May 8, 2018, 8:30 a.m. to 12:00 p.m.
Agenda: Pragmatic Trials at NIH; Rehabilitation 2030: WHO
Effort; Scientific Presentation on Multimodal Approaches.
Place: NICHD Offices, 6710B Rockledge Drive, Rooms 1425/1427,
Bethesda, MD 20892.
Contact Person: Ralph M. Nitkin, Ph.D., Deputy Director,
National Center for Medical Rehabilitation Research (NCMRR), Eunice
Kennedy Shriver National Institute of Child Health and Human
Development, NIH, DHHS, 6710B Rockledge Drive, Room 2116, MSC 7002,
Bethesda, MD 20892, (301) 402-4206, [email protected].
Information is also available on the Institute's/Center's home
page: https://www.nichd.nih.gov/about/advisory/nabmrr/Pages/index.aspx where the current roster and minutes from past meetings
are posted.
(Catalogue of Federal Domestic Assistance Program Nos. 93.864,
Population Research; 93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation Research; 93.209,
Contraception and Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: March 23, 2018.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-06258 Filed 3-28-18; 8:45 am]
BILLING CODE 4140-01-P